Minocycline (free base) | CAS# 10118-90-8 (free base) | tetracycline-resistant STAPHYLOCOCCUS

MedKoo Cat#: 413027 | Name: Minocycline (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Minocycline (free base) is A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.

Chemical Structure

Minocycline (free base)

CAS#10118-90-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413027

Name: Minocycline (free base)

CAS#: 10118-90-8 (free base)

Chemical Formula: C23H27N3O7

Exact Mass: 457.1849

Molecular Weight: 457.48

Elemental Analysis: C, 60.39; H, 5.95; N, 9.19; O, 24.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

13614-98-7 (HCl) 10118-90-8 (free base) 128420-71-3 (HCl hydrate)

Synonym

Minocycline (free base), HSDB3130; HSDB-3130; HSDB 3130

IUPAC/Chemical Name

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

InChi Key

DYKFCLLONBREIL-KVUCHLLUSA-N

InChi Code

InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1

SMILES Code

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4N(C)C)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 457.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002086. doi: 10.1002/14651858.CD002086.pub2. PMID: 22895927; PMCID: PMC7017847. 2: Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord. 2018 Feb;227:219-225. doi: 10.1016/j.jad.2017.10.042. Epub 2017 Oct 28. PMID: 29102836. 3: Jonas M, Cunha BA. Minocycline. Ther Drug Monit. 1982;4(2):137-45. PMID: 7048646. 4: Allen JC. Minocycline. Ann Intern Med. 1976 Oct;85(4):482-7. doi: 10.7326/0003-4819-85-4-482. PMID: 788583. 5: Minocycline foam (Amzeeq) for acne. Med Lett Drugs Ther. 2020 May 4;62(1597):68-70. PMID: 32555112. 6: Zheng W, Zhu XM, Zhang QE, Cheng G, Cai DB, He J, Ng CH, Ungvari GS, Peng XJ, Ning YP, Xiang YT. Adjunctive minocycline for major mental disorders: A systematic review. J Psychopharmacol. 2019 Oct;33(10):1215-1226. doi: 10.1177/0269881119858286. Epub 2019 Jul 11. PMID: 31294649. 7: Haghi-Aminjan H, Asghari MH, Goharbari MH, Abdollahi M. A systematic review on potential mechanisms of minocycline in kidney diseases. Pharmacol Rep. 2017 Aug;69(4):602-609. doi: 10.1016/j.pharep.2017.02.001. Epub 2017 Feb 8. PMID: 28500967. 8: Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. PMID: 18977395. 9: Nagarakanti S, Bishburg E. Is Minocycline an Antiviral Agent? A Review of Current Literature. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):4-8. doi: 10.1111/bcpt.12444. Epub 2015 Aug 2. PMID: 26177421. 10: Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol. 2010;11(5):327-41. doi: 10.2165/11319280-000000000-00000. PMID: 20642295.